Clinical trial
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes…
NCT00467376 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00467376 |
|---|---|
| Title | Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus |
| Official title | 12-week, Multicenter, Controlled, Open, 3:1 Randomized, Parallel Clinical Trial Comparing Insulin Glulisine With Regular Human Insulin (Insulin Lispro) Injected Subcutaneously in Subjects With Type 1 or 2 Diabetes Mellitus Also Using Lantus (Insulin Glargine) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Insulin Glulisine, Lispro, Insulin Glargine |
| Enrollment | 485 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2008 |
| First posted | Apr 30, 2007 |
| Last update posted | Sep 15, 2009 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: